Global Zoster Vaccine Market Size By Type (Live, Recombinant), By Application (Government Institution, Private Sector), By Region, And Segment Forecasts, 2023 to 2032

The Global Zoster Vaccine Market was valued at USD 3.2 billion in 2023 and is projected to reach USD 6.1 billion by 2031, growing at a CAGR of 8.5% during the forecast period from 2023 to 2031. This growth is driven by the increasing incidence of shingles among aging populations, rising awareness of preventive vaccination, and the introduction of new recombinant vaccines with improved efficacy. Government immunization programs and growing healthcare expenditure in emerging economies are also significantly contributing to the expanding market.

Drivers:

1. Aging Global Population:

The increasing number of individuals over the age of 50, who are more susceptible to shingles, is a primary driver. The elderly population is at higher risk of complications, making preventive vaccination a critical public health priority.

2. Rising Awareness and Government Initiatives:

Awareness campaigns by healthcare organizations and governments are driving vaccine uptake. National immunization programs in developed regions, such as the U.S. and parts of Europe, include zoster vaccines for older adults.

3. Improved Vaccine Efficacy with Recombinant Formulations:

The launch of recombinant zoster vaccines (RZV) like Shingrix has revolutionized the market, offering higher efficacy compared to live attenuated vaccines. These newer options have significantly boosted public and provider confidence.

Restraints:

1. High Cost of Vaccination:

The relatively high cost of zoster vaccines, particularly in low-income regions, remains a barrier. Limited insurance coverage in some countries further impedes access to these preventive measures.

2. Limited Penetration in Emerging Markets:

In developing nations, lack of awareness, infrastructure, and prioritization of other vaccines over adult immunization hinders market penetration for zoster vaccines.

Opportunity:

1. Expansion into Emerging Economies:

The increasing focus on adult immunization in emerging markets, combined with improved healthcare access and infrastructure, presents significant opportunities for growth.

2. Development of Combination Vaccines:

R&D investments into multi-disease or combination vaccines for elderly populations could open new avenues, streamlining immunization and reducing healthcare burdens.

Market by System Type Insights:

The Recombinant Zoster Vaccine (RZV) segment accounted for the largest market share in 2023. Owing to its superior efficacy and safety profile, particularly among immunocompromised individuals, RZV is rapidly replacing the live attenuated variant. The Live Attenuated Zoster Vaccine (LZV) segment is witnessing a gradual decline but remains relevant in markets where RZV is yet to be widely adopted.

Market by End-use Insights:

The Hospitals & Clinics segment dominated the market in 2023, contributing to more than 60% of the global revenue. These facilities serve as primary points for immunization, supported by public health systems. The Retail Pharmacies segment is expected to grow rapidly due to increasing over-the-counter availability and public preference for convenient access.

Market by Regional Insights:

North America held the largest market share in 2023, driven by strong public awareness, insurance coverage, and established healthcare infrastructure. Asia-Pacific is projected to register the highest CAGR during the forecast period, propelled by expanding healthcare access, aging demographics, and increasing investment in adult vaccination programs in countries like Japan, China, and India.

Competitive Scenario:

Key players operating in the Global Zoster Vaccine Market include:

GlaxoSmithKline plc (GSK) – market leader with its recombinant vaccine Shingrix.

Merck & Co., Inc. – manufacturer of Zostavax, a live attenuated vaccine.

Pfizer Inc., Sanofi S.A., and Emergent BioSolutions Inc. are actively exploring new formulations or partnerships in the space.

Key strategies include product innovation, expansion into emerging markets, strategic partnerships with governments, and increasing production capacities.

Scope of Work – Global Zoster Vaccine Market

Key Market Developments:

2023: GSK expanded its manufacturing capacity for Shingrix in Europe to meet increasing global demand.

2024: Merck announced efforts to enhance cold chain distribution for Zostavax in developing markets.

2025: Pfizer entered a strategic research collaboration to co-develop next-gen recombinant zoster vaccines tailored for immunocompromised populations.

FAQs:

1) What is the current market size of the Global Zoster Vaccine Market?

The Global Zoster Vaccine Market was valued at USD 3.2 billion in 2023.

2) What is the major growth driver of the Global Zoster Vaccine Market?

The primary growth driver is the rising elderly population and the increasing awareness of shingles prevention through vaccination.

3) Which is the largest region during the forecast period in the Global Zoster Vaccine Market?

North America is the largest region, supported by established healthcare systems and widespread vaccine adoption.

4) Which segment accounted for the largest market share in Global Zoster Vaccine Market?

The Recombinant Zoster Vaccine (RZV) segment accounted for the largest share due to its higher efficacy.

5) Who are the key market players in the Global Zoster Vaccine Market?

Key players include GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., and Emergent BioSolutions Inc.